VRTX Beginning!
Fundamental & Chart
Not for investment advice, personal notes only
Chart:
identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives.
So far trend line remains intact, neckline of H&S shows no particular bearish inclination
Fundamentals:
Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations.
In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial.
Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020.
Currently seeking acquisition opportunities
Let's wait and see
Not for investment advice, personal notes only
Chart:
identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives.
So far trend line remains intact, neckline of H&S shows no particular bearish inclination
Fundamentals:
Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations.
In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial.
Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020.
Currently seeking acquisition opportunities
Let's wait and see
Отказ от ответственности
Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.